Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Evelo Biosciences (EVLO – Research Report) yesterday and set a price target of $2.00. The company’s shares closed yesterday at $0.10.
According to TipRanks, Purohit is an analyst with an average return of -29.3% and an 11.86% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Ascendis Pharma, and Incyte.
Evelo Biosciences has an analyst consensus of Hold, with a price target consensus of $2.03.
See Insiders’ Hot Stocks on TipRanks >>
EVLO market cap is currently $11.09M and has a P/E ratio of -0.07.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Read More on EVLO:
- Evelo Biosciences Provides Clinical Updates
- Evelo Biosciences price target lowered to $5 from $10 at BMO Capital
- Evelo Biosciences downgraded to Neutral from Overweight at Cantor Fitzgerald
- Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Evelo Biosciences reports Q4 EPS (21c), consensus (28c)
